U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24N2O9.ClH
Molecular Weight 496.895
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYTETRACYCLINE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C

InChI

InChIKey=UBDNTYUBJLXUNN-IFLJXUKPSA-N
InChI=1S/C22H24N2O9.ClH/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29;/h4-6,12-14,17,25,27-29,32-33H,1-3H3,(H2,23,31);1H/t12-,13-,14+,17+,21-,22+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C22H24N2O9
Molecular Weight 460.434
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxytetracycline, a tetracycline analog isolated from the actinomycete streptomyces rimosus, was the second of the broad-spectrum tetracycline group of antibiotics to be discovered The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms for animal use only. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in dogs); ocular infections due to secondary bacterial complications associated with distemper in dogs; and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in dogs. Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken. Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TERRAMYCIN W/ POLYMYXIN B SULFATE

Approved Use

Terramycin Ophthalmic Ointment with Polymyxin B Sulfate is indicated for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms, including infections due to streptococci, rickettsiae, E. coli, and A. aerogenes, such as conjunctivitis, keratitis, pink eye, corneal ulcer, blepharitis in dogs, cats, cattle, sheep, and horses; ocular infections due to secondary bacterial complications of distemper in dogs, and bacterial inflammatory conditions which may occur secondary to other infectious diseases in the above species.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15 μg/mL
250 mg/kg bw single, oral
dose: 250 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYTETRACYCLINE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
90.72 μg × h/mL
250 mg/kg bw single, oral
dose: 250 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYTETRACYCLINE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.46 h
250 mg/kg bw single, oral
dose: 250 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYTETRACYCLINE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Other AEs: Nausea, Diarrhoea...
Other AEs:
Nausea (grade 1-2, 15 patients)
Diarrhoea (grade 1-2, 13 patients)
Rash (grade 1-2, 1 patient)
Lassitude (grade 1-2, 1 patient)
Nausea (grade 3, 10 patients)
Diarrhoea (grade 3, 5 patients)
Nausea (grade 4, 1 patient)
Diarrhoea (grade 4, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Lassitude grade 1-2, 1 patient
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Rash grade 1-2, 1 patient
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Diarrhoea grade 1-2, 13 patients
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Nausea grade 1-2, 15 patients
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Nausea grade 3, 10 patients
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Diarrhoea grade 3, 5 patients
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Diarrhoea grade 4, 1 patient
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Nausea grade 4, 1 patient
250 mg 4 times / day steady, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: steady
Dose: 250 mg, 4 times / day
Sources:
unhealthy, adult
n = 369
Health Status: unhealthy
Condition: cough and cold
Age Group: adult
Sex: unknown
Population Size: 369
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client
Page: 1.0
no
Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client
Page: 1.0
no
Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client
Page: 5.0
yes [Inhibition 5 uM]
Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client
Page: 5.0
yes [Inhibition 500 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Acute renal failure following overdosage of oxyterracin].
1970 Jan
Azotaemia aggravated by tetracycline.
1970 Jan 3
Azotaemia aggravated by oxytetracycline.
1971 Nov 16
Case report: coma due to oxytetracycline.
1977
Oxytetracycline nephrotoxicosis in two dogs.
1980 Mar 15
Screening for new compounds with antiherpes activity.
1984 Oct
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
1988 Feb
In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.
1990 Aug
Contact allergies to topical corticosteroids.
1993 Mar
Cholestatic hepatitis associated with flucloxacillin.
1993 May 3
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Minocycline-induced chronic interstitial nephritis?
1996 Mar
Oxytetracycline-induced nephrotoxicosis in dogs after intravenous administration for experimental bone labeling.
1996 Oct
Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets.
2000 Oct
Human organic anion transporters mediate the transport of tetracycline.
2002 Jan
In vitro effects of oxytetracycline on matrix metalloproteinase-1 mRNA expression and on collagen gel contraction by cultured myofibroblasts obtained from the accessory ligament of foals.
2004 Apr
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.
2005 Jul
Drug treatment during pregnancy and isolated orofacial clefts in hungary.
2007 Mar
Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.
2010 Jul
Impact of isoflupredone acetate treatment on clinical signs and weight gain in weanling heifers with experimentally induced Mannheimia haemolytica bronchopneumonia.
2011 Dec
Environmental impact on vascular development predicted by high-throughput screening.
2011 Nov
Effect of pharmaceuticals exposure on acetylcholinesterase (AchE) activity and on the expression of AchE gene in the monogonont rotifer, Brachionus koreanus.
2013 Nov
Molecular and Cellular Effects Induced in Mytilus galloprovincialis Treated with Oxytetracycline at Different Temperatures.
2015
Patents

Sample Use Guides

For Animal Use Only: topically to the eye 2–4 times daily.
Route of Administration: Other
It was investigated the possible toxic mechanism of oxytetracycline (OTC) on the human red blood cells (hRBCs). The experimental results indicate that OTC can cause a decline in the function of the antioxidant defense system of hRBCs, resulting in oxidative stress. OTC can bring about morphological changes to hRBCs, and further leads to hemolysis, when the concentration of OTC is over 8×10(-5) M (about 164 µg/ml). At a low OTC concentration, below 4×10(-5) M (82 µg/ml), OTC can enhance the activity of ATP enzyme of hRBCs, known as hormesis. However, at a high concentration, above 4×10(-5) M (about 82 µg/ml), the ATP enzymatic activity was inhibited, affecting the function of hRBCs.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:38 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:38 GMT 2023
Record UNII
4U7K4N52ZM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYTETRACYCLINE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [MI]
Common Name English
TERRAMYCIN HYDROCHLORIDE
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [USP-RS]
Common Name English
4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
OXYTETRACYCLINE HCL
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [VANDF]
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [MART.]
Common Name English
Oxytetracycline hydrochloride [WHO-DD]
Common Name English
OXY-KESSO-TETRA
Brand Name English
OXYTETRACYCLINE HYDROCHLORIDE [WHO-IP]
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [JAN]
Common Name English
TERRA-CORTRIL COMPONENT OXYTETRACYCLINE HYDROCHLORIDE
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
OXYTETRACYCLINE HYDROCHLORIDE COMPONENT OF TERRA-CORTRIL
Common Name English
OXYTETRACYCLINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,6,10,12,12A-HEXAHYDROXY-6-METHYL-1,11-DIOXO-, MONOHYDROCHLORIDE, (4S-(4.ALPHA.,4A.ALPHA.,5.ALPHA.,5A.ALPHA.,6.BETA.,12A.ALPHA.))-
Common Name English
Classification Tree Code System Code
CFR 21 CFR 520.1660B
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
CFR 21 CFR 520.1660C
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
CFR 21 CFR 333.120
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
CFR 21 CFR 522.1662
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
EPA PESTICIDE CODE 6308
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
CFR 21 CFR 522.1662A
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
NCI_THESAURUS C1595
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
CFR 21 CFR 522.1662B
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID5021097
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
ALANWOOD
oxytetracycline hydrochloride
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
SMS_ID
100000092050
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
FDA UNII
4U7K4N52ZM
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
NCI_THESAURUS
C47649
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
OXYTETRACYCLINE HYDROCHLORIDE
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY Description: A yellow, crystalline powder; odourless. Solubility: Soluble in 2 parts of water and in 45 parts of ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antibacterial drug. Storage: Oxytetracycline hydrochloride should be kept in a tightly closed container, protected from light. Labelling: The designation sterile Oxytetracycline hydrochloride indicates that the substance complies with the additionalrequirements for sterile Oxytetracycline hydrochloride and may be used for parenteral administration or for other sterile applications. Additional information: Oxytetracycline hydrochloride is hygroscopic. Even in the absence of light, it is gradually degraded onexposure to a humid atmosphere, the decomposition being faster at higher temperatures. Dissolved in water it becomes turbid onstanding owing to the separation of the base caused through partial hydrolysis of the hydrochloride. It deteriorates in solutions ofpH below 2, and is rapidly destroyed by alkali hydroxide solutions. Definition: Oxytetracycline hydrochloride contains not less than 870 International Units of Oxytetracycline per mg, calculated withreference to the anhydrous substance.
RS_ITEM_NUM
1491015
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
DAILYMED
4U7K4N52ZM
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
218-161-2
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
MERCK INDEX
m8345
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1517
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
EVMPD
SUB14740MIG
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
CAS
15000-39-2
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
NON-SPECIFIC STOICHIOMETRY
CAS
2058-46-0
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
DRUG BANK
DBSALT000645
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY
RXCUI
4780
Created by admin on Fri Dec 15 15:00:38 GMT 2023 , Edited by admin on Fri Dec 15 15:00:38 GMT 2023
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
total of impurities D, E and F (eluting between the latter two): not more than the area of the peak due to impurity E in the chromatogram obtained with reference solution (g) (2.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
total of impurities D, E and F (eluting between the latter two): not more than the area of the peak due to impurity E in the chromatogram obtained with reference solution (g) (2.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
total of impurities D, E and F (eluting between the latter two): not more than the area of the peak due to impurity E in the chromatogram obtained with reference solution (g) (2.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
not more than 4 times the area of the peak due to impurity A in the chromatogram obtained with reference solution
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY